In the case analyses (Fig. 5c), genes such as TMEM92 and C1orf226 showed consistent expression in pretreatment surgically resected tumor tissues, and posttreatment blood may be indicators of GBM. This evidence concerns the gene TMEM92 and glioblastoma.